ArcellxACLX
ACLX
About: Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Employees: 163
0
Funds holding %
of 7,435 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
1% more funds holding
Funds holding: 195 [Q1] → 197 (+2) [Q2]
0.92% less ownership
Funds ownership: 112.07% [Q1] → 111.15% (-0.92%) [Q2]
1% less capital invested
Capital invested by funds: $4.04B [Q1] → $4B (-$40.6M) [Q2]
14% less funds holding in top 10
Funds holding in top 10: 14 [Q1] → 12 (-2) [Q2]
28% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 82
55% less call options, than puts
Call options by funds: $16.6M | Put options by funds: $36.9M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$110
56%
upside
Avg. target
$119
70%
upside
High target
$133
89%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank George Farmer | 89%upside $133 | Sector Outperform Maintained | 31 Jul 2025 |
Citigroup Geoff Meacham | 56%upside $110 | Buy Initiated | 17 Jun 2025 |
HC Wainwright & Co. Emily Bodnar | 64%upside $115 | Buy Reiterated | 16 Jun 2025 |
Financial journalist opinion
Based on 4 articles about ACLX published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.
Negative
Zacks Investment Research
2 weeks ago
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago.
Neutral
The Motley Fool
2 weeks ago
Arcellx (ACLX) Q2 Revenue Drops 72%
Arcellx (ACLX) Q2 Revenue Drops 72%
Neutral
Business Wire
2 weeks ago
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel's potential to be a life-changing therapy for mu.
Neutral
Seeking Alpha
1 month ago
Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market
Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data support the potential of anito-cel, especially in 2nd-line+ multiple myeloma patients who failed prior therapies. The FDA has allowed a dual primary endpoint—progression-free survival and MRD-negativity—in the ongoing phase 3 iMMagine-3 study, enhancing regulatory prospects.
Negative
Investors Business Daily
2 months ago
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Neutral
Business Wire
3 months ago
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at.
Neutral
Business Wire
3 months ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.
Negative
Zacks Investment Research
3 months ago
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.14 per share a year ago.
Neutral
Business Wire
3 months ago
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. “Delivering therapies that can positively impact patients' lives is our mission,” said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. “We are pleased tha.
Charts implemented using Lightweight Charts™